# DermaIQ Financial Projections (2025-2030)

## Financial Summary

DermaIQ's financial projections demonstrate strong growth potential with multiple revenue streams, attractive unit economics, and a clear path to profitability. Our business model combines consumer subscription revenue with B2B partnerships, creating a diversified and scalable revenue base.

## Key Financial Highlights

- **Seed Funding**: £250,000 (May 2025)
- **Series A**: £2M (Projected Q3 2026)
- **Monthly Break-even**: Month 10 (February 2026)
- **Cumulative Break-even**: Month 19 (November 2026)
- **Year 3 Revenue**: £5.5M
- **Year 5 Revenue**: £24.5M
- **Year 5 EBITDA Margin**: 45%
- **LTV:CAC Ratio**: 14.4:1

## 5-Year Revenue Projections

| Revenue Stream | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 |
|----------------|--------|--------|--------|--------|--------|
| Premium Subscriptions | £240,000 | £900,000 | £3,000,000 | £6,480,000 | £12,600,000 |
| B2B API Access | £60,000 | £250,000 | £1,500,000 | £3,600,000 | £7,200,000 |
| White Label Solutions | £0 | £50,000 | £750,000 | £2,000,000 | £3,500,000 |
| Data Insights | £0 | £20,000 | £100,000 | £320,000 | £700,000 |
| Affiliate Revenue | £20,000 | £30,000 | £150,000 | £400,000 | £500,000 |
| **Total Revenue** | **£320,000** | **£1,250,000** | **£5,500,000** | **£12,800,000** | **£24,500,000** |
| **YoY Growth** | - | **291%** | **340%** | **133%** | **91%** |

## User Growth Projections

| Metric | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 |
|--------|--------|--------|--------|--------|--------|
| Total Users | 50,000 | 125,000 | 250,000 | 450,000 | 750,000 |
| Free Users | 41,500 | 100,000 | 187,500 | 315,000 | 487,500 |
| Paying Users | 8,500 | 25,000 | 62,500 | 135,000 | 262,500 |
| Conversion Rate | 17% | 20% | 25% | 30% | 35% |
| Monthly Active Users | 30,000 | 87,500 | 187,500 | 360,000 | 637,500 |
| B2B Clients | 10 | 25 | 75 | 150 | 300 |

## Unit Economics

### Customer Acquisition

| Metric | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 |
|--------|--------|--------|--------|--------|--------|
| Marketing Spend | £125,000 | £250,000 | £500,000 | £900,000 | £1,500,000 |
| New Users Acquired | 50,000 | 75,000 | 125,000 | 200,000 | 300,000 |
| Cost Per Acquisition (CPA) | £2.50 | £3.33 | £4.00 | £4.50 | £5.00 |
| Paying User CPA | £14.71 | £16.67 | £16.00 | £15.00 | £14.29 |

### Customer Lifetime Value

| Metric | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 |
|--------|--------|--------|--------|--------|--------|
| Monthly Subscription | £3.99 | £3.99 | £4.99 | £4.99 | £4.99 |
| Average Retention (months) | 9 | 12 | 15 | 18 | 21 |
| Lifetime Value (LTV) | £35.90 | £47.88 | £74.85 | £89.82 | £104.79 |
| LTV:CAC Ratio | 14.4:1 | 14.4:1 | 18.7:1 | 20.0:1 | 21.0:1 |

## Profit & Loss Projection

| Category | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 |
|----------|--------|--------|--------|--------|--------|
| **Revenue** | £320,000 | £1,250,000 | £5,500,000 | £12,800,000 | £24,500,000 |
| **Cost of Revenue** | £90,000 | £300,000 | £990,000 | £1,920,000 | £3,185,000 |
| Server & Infrastructure | £50,000 | £150,000 | £450,000 | £800,000 | £1,225,000 |
| Payment Processing | £15,000 | £60,000 | £240,000 | £520,000 | £960,000 |
| Customer Support | £25,000 | £90,000 | £300,000 | £600,000 | £1,000,000 |
| **Gross Profit** | £230,000 | £950,000 | £4,510,000 | £10,880,000 | £21,315,000 |
| **Gross Margin** | 72% | 76% | 82% | 85% | 87% |
| **Operating Expenses** | £410,000 | £825,000 | £2,860,000 | £5,760,000 | £10,285,000 |
| R&D | £150,000 | £300,000 | £1,100,000 | £2,300,000 | £4,000,000 |
| Sales & Marketing | £125,000 | £250,000 | £900,000 | £1,800,000 | £3,500,000 |
| General & Administrative | £135,000 | £275,000 | £860,000 | £1,660,000 | £2,785,000 |
| **EBITDA** | -£180,000 | £125,000 | £1,650,000 | £5,120,000 | £11,030,000 |
| **EBITDA Margin** | -56% | 10% | 30% | 40% | 45% |
| Depreciation & Amortization | £20,000 | £40,000 | £100,000 | £200,000 | £350,000 |
| **EBIT** | -£200,000 | £85,000 | £1,550,000 | £4,920,000 | £10,680,000 |
| Taxes | £0 | £16,150 | £294,500 | £934,800 | £2,029,200 |
| **Net Income** | -£200,000 | £68,850 | £1,255,500 | £3,985,200 | £8,650,800 |
| **Net Margin** | -63% | 6% | 23% | 31% | 35% |

## Cash Flow Projection

| Category | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 |
|----------|--------|--------|--------|--------|--------|
| **Beginning Cash** | £250,000 | £70,000 | £2,158,850 | £3,514,350 | £7,699,550 |
| **Cash Inflows** | £320,000 | £3,250,000 | £5,500,000 | £12,800,000 | £24,500,000 |
| Revenue | £320,000 | £1,250,000 | £5,500,000 | £12,800,000 | £24,500,000 |
| Investment | £0 | £2,000,000 | £0 | £0 | £0 |
| **Cash Outflows** | £500,000 | £1,161,150 | £4,144,500 | £8,614,800 | £15,849,200 |
| Operating Expenses | £410,000 | £825,000 | £2,860,000 | £5,760,000 | £10,285,000 |
| Cost of Revenue | £90,000 | £300,000 | £990,000 | £1,920,000 | £3,185,000 |
| Capital Expenditures | £0 | £20,000 | £0 | £0 | £350,000 |
| Taxes | £0 | £16,150 | £294,500 | £934,800 | £2,029,200 |
| **Net Cash Flow** | -£180,000 | £2,088,850 | £1,355,500 | £4,185,200 | £8,650,800 |
| **Ending Cash** | £70,000 | £2,158,850 | £3,514,350 | £7,699,550 | £16,350,350 |

## Funding Requirements

### Seed Round (Q2 2025): £250,000

**Use of Funds:**
- Product Development: £100,000 (40%)
- Initial Marketing: £75,000 (30%)
- Team Expansion: £50,000 (20%)
- Operations & Legal: £25,000 (10%)

**Key Milestones to Be Achieved:**
- MVP launch with core functionality
- 50,000 users by end of Year 1
- Strategic partnerships formalized
- Preparation for Series A

### Series A (Q3 2026): £2,000,000

**Use of Funds:**
- Product Development: £800,000 (40%)
- Marketing & User Acquisition: £600,000 (30%)
- Team Expansion: £400,000 (20%)
- Operations & Infrastructure: £200,000 (10%)

**Key Milestones to Be Achieved:**
- Enhanced personalization features
- Android app launch
- B2B API development
- 250,000 users by end of Year 3
- International expansion preparation

## Sensitivity Analysis

### Upside Scenario (+20%)

| Metric | Year 1 | Year 3 | Year 5 |
|--------|--------|--------|--------|
| Users | 60,000 | 300,000 | 900,000 |
| Revenue | £384,000 | £6,600,000 | £29,400,000 |
| EBITDA | -£140,000 | £2,310,000 | £14,700,000 |
| EBITDA Margin | -36% | 35% | 50% |

### Downside Scenario (-20%)

| Metric | Year 1 | Year 3 | Year 5 |
|--------|--------|--------|--------|
| Users | 40,000 | 200,000 | 600,000 |
| Revenue | £256,000 | £4,400,000 | £19,600,000 |
| EBITDA | -£220,000 | £990,000 | £7,840,000 |
| EBITDA Margin | -86% | 23% | 40% |

## Key Financial Assumptions

1. **User Growth:**
   - Initial growth driven by UK market focus
   - Year 3+ expansion into EU markets
   - Marketing efficiency improves with brand recognition

2. **Monetization:**
   - Free-to-Premium conversion rate increases from 17% to 35% over 5 years
   - B2B revenue becomes increasingly significant from Year 3
   - Premium pricing increases from £3.99 to £4.99 in Year 3

3. **Costs:**
   - Engineering team grows from 5 to 25 over 5 years
   - Marketing spend maintained at 25-30% of revenue
   - Infrastructure costs benefit from economies of scale

4. **Investment:**
   - Seed round (£250K) in Q2 2025
   - Series A (£2M) in Q3 2026
   - No additional funding required to reach profitability

## Risk Factors and Mitigation

1. **User Acquisition Costs Increase**
   - Mitigation: Diversify acquisition channels; focus on organic growth and referrals

2. **Lower Conversion Rate**
   - Mitigation: A/B testing of premium features; enhanced value proposition; tiered pricing

3. **Delayed B2B Revenue**
   - Mitigation: Focus on consumer growth; adjust operating expenses; explore additional consumer monetization

4. **Competitive Pressure**
   - Mitigation: Accelerate product roadmap; emphasize unique differentiators; strategic partnerships

5. **Technical Development Delays**
   - Mitigation: Phased approach to feature releases; flexible resource allocation; technical contingency planning

## Conclusion

DermaIQ presents a compelling financial opportunity with strong unit economics, multiple revenue streams, and a clear path to profitability. Our projections demonstrate the potential to build a £24.5M revenue business within 5 years, with healthy EBITDA margins of 45%.

The initial seed investment of £250,000 will enable us to achieve critical early milestones, setting the foundation for significant growth and positioning the company for a successful Series A round in Year 2. With a projected LTV:CAC ratio of 14.4:1, DermaIQ offers an efficient growth model with attractive returns for early investors.

*Note: These projections are based on current market conditions and assumptions. Actual results may vary. Financial projections in GBP (£). Current exchange rate: £1 = $1.31 USD.*
